Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice

Clicks: 215
ID: 271166
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #7 of 7 articles by views in critical care (london, england)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To prevent clotting in the extracorporeal circuit during continuous renal replacement therapy (CRRT) anticoagulation is required. Heparin is still the most commonly used anticoagulant. However, heparins increase the risk of bleeding, especially in critically ill patients. Evidence has accumulated th …
Reference Key
hm2012criticalbench-to-bedside Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Oudemans-van Straaten HM;Ostermann M;;
Journal critical care (london, england)
Year 2012
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/23216871
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine anticoagulants / adverse effects anticoagulants / therapeutic use* pmid:23216871 pmc3672558 doi:10.1186/cc11645 heleen m oudemans-van straaten marlies ostermann blood coagulation / drug effects citric acid / adverse effects citric acid / therapeutic use* renal replacement therapy / methods*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.